Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond L Comenzo

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ DysfunctionMorie A Gertz, Heather Landau, Raymond L Comenzo, et al.
British Journal of Haematology|September 28, 2007
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trialAdam D Cohen, Ping Zhou, Joanne Chou, et al.
Transfusion|June 29, 2012
Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusionsHans Klingemann, Carrie Grodman, Elliott Cutler, et al.
Leukemia & Lymphoma|June 1, 2022
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approachOscar B Lahoud, Heather Landau, James Nguyen, et al.
Cancer Immunity|July 24, 2003
Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of diseaseMadhav V Dhodapkar, Keren Osman, Julie Teruya-Feldstein, et al.
Leukemia|June 25, 2021
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosisAngela Dispenzieri, Efstathios Kastritis, Ashutosh D Wechalekar, et al.
Journal of Clinical Pharmacology|October 28, 2021
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain AmyloidosisMan Melody Luo, Peijuan Penny Zhu, Ivo Nnane, et al.
Blood|May 28, 2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosisVaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, et al.
British Journal of Haematology|January 10, 2006
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myelomaHani Hassoun, Lilian Reich, Virginia M Klimek, et al.
Blood|May 13, 2011
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 studyDonna E Reece, Ute Hegenbart, Vaishali Sanchorawala, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ DysfunctionMorie A Gertz, Heather Landau, Raymond L Comenzo, et al.
British Journal of Haematology|September 28, 2007
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trialAdam D Cohen, Ping Zhou, Joanne Chou, et al.
Transfusion|June 29, 2012
Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusionsHans Klingemann, Carrie Grodman, Elliott Cutler, et al.
Leukemia & Lymphoma|June 1, 2022
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approachOscar B Lahoud, Heather Landau, James Nguyen, et al.
Cancer Immunity|July 24, 2003
Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of diseaseMadhav V Dhodapkar, Keren Osman, Julie Teruya-Feldstein, et al.
Leukemia|June 25, 2021
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosisAngela Dispenzieri, Efstathios Kastritis, Ashutosh D Wechalekar, et al.
Journal of Clinical Pharmacology|October 28, 2021
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain AmyloidosisMan Melody Luo, Peijuan Penny Zhu, Ivo Nnane, et al.
Blood|May 28, 2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosisVaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, et al.
British Journal of Haematology|January 10, 2006
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myelomaHani Hassoun, Lilian Reich, Virginia M Klimek, et al.
Blood|May 13, 2011
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 studyDonna E Reece, Ute Hegenbart, Vaishali Sanchorawala, et al.
Pageof 9